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Changes to the redox status of biological systems have been implicated in the pathogenesis of 
a wide variety of disorders including cancer, ischemic-reperfusion (I/R) injury and 
neurodegeneration. In times of metabolic stress e.g. ischemia / reperfusion, reactive oxygen 
species (ROS) production overwhelms the intrinsic antioxidant capacity of the cell, damaging 
vital cellular components. The ability to quantify ROS changes in vivo, is therefore essential 
to understanding their biological role. Here we evaluate the suitability of a novel reversible 
profluorescent probe containing a redox-sensitive nitroxide moiety (methyl ester 
tetraethylrhodamine nitroxide, ME-TRN), as an in vivo, real-time reporter of retinal oxidative 
status. The reversible nature of the probe's response offers the unique advantage of being able 
to monitor redox changes in both oxidizing and reducing directions in real time. After 
intravitreal administration of the ME-TRN probe, we induced ROS production in rat retina 
using an established model of complete, acute retinal ischemia followed by reperfusion. After 
restoration of blood flow, retinas were imaged using a Micron III rodent fundus fluorescence 
imaging system, to quantify the redox-response of the probe. Fluorescent intensity declined 
during the first 60 minutes of reperfusion. The ROS-induced change in probe fluorescence 
was ameliorated with the retinal antioxidant, lutein. Fluorescence intensity in non-ischemic 
eyes did not change significantly. This new probe and imaging technology provide a 
reversible and real-time response to oxidative changes and may allow the in vivo testing of 
antioxidant therapies of potential benefit to a range of diseases linked to oxidative stress.	  




DMSO: Dimethyl sulfoxide 
ERG: Electroretinogram 
GFAP: Glial fibrillary acidic protein 
IBA-1: Ionized calcium binding adaptor molecule 1 
IOP: Intraocular pressure 
I/R: Ischemia-reperfusion 
ME-TRN: Methyl ester tetraethylrhodamine nitroxide 
OPs: Oscillatory potentials 
PFN: Profluorescent nitroxides 
RGC: Retinal ganglion cell 
ROS: Reactive oxygen species 
AMD: Age-related macular degeneration 
The accumulation of free radicals (reactive oxygen species, ROS), has been implicated in 
numerous neurodegenerative diseases, including Parkinson’s disease (Ray et al., 2014), 
Alzheimer’s disease (Aliev et al., 2013), cardiac diseases (Schwarz et al., 2014) and the 
major degenerative visual diseases such as glaucoma (Almasieh et al., 2012; Chrysostomou et 
al., 2013; Yuki et al., 2011), diabetic retinopathy (Wilkinson-Berka et al., 2013) and age-
related macular degeneration (AMD) (Seo et al., 2012). Neurodegeneration is defined by the 
progressive loss of specific neuronal cell populations, with extensive evidence verifying 
oxidative stress a contributing factor to disease pathogenesis (Barnham et al., 2004; Scherz-
Shouval and Elazar, 2011). ROS are natural by-products of cellular metabolism essential in 
cell signalling and homeostasis, however when cellular ROS production overwhelms the 
intrinsic antioxidant capacity, they become extremely damaging to vital cellular components 
which can lead to irreversible changes and cell death (Tezel, 2006). In response to this 
imbalance in the cellular redox environment, i.e. oxidative stress, cells respond by activating 
various defence mechanisms (Scherz-Shouval and Elazar, 2007) such as up-regulation of 
antioxidants and/or the removal of damaged proteins and organelles by autophagy; these 
assist cells in restoring homeostasis (Hamanaka and Chandel, 2010; Kiffin et al., 2006; 
Lemasters, 2005; Scherz-Shouval and Elazar, 2007). Accumulating data has implicated 
mitochondria as the main source for regulation of autophagy by ROS (Azad et al., 2009; 
Chen et al., 2007; Hamanaka and Chandel, 2010; Scherz-­‐Shouval et al., 2007). Significantly, 
whilst retinal photoreceptors have the highest density of mitochondria of all central nervous 
system neurones  (Kageyama and Wong-Riley, 1984), retinal ganglion cells are also 
particularly susceptible to mitochondrial dysfunction, which has critical importance in the 
initiation of glaucoma and subsequent vision loss (Chrysostomou et al., 2013; Osborne and 
del Olmo-Aguado, 2013).   
Retinal ischemic-reperfusion (I/R) injury induced by transient elevation of intraocular 
pressure (IOP) in animal models, results in necrosis and apoptosis of cells in both the 
ganglion cell layer and inner nuclear layer (Hughes, 1991; Kuroiwa et al., 1998; Li et al., 
2009; Oharazawa et al., 2010). Excessive elevation of IOP impairs blood flow dynamics in 
the retina and the optic nerve head, reducing the delivery of energy and nutrients required for 
cell survival, thus rendering them susceptible to additional insults (Osborne, 2008). Extensive 
evidence for this pathological mechanism has lead to the vascular theory of glaucoma (Arend 
et al., 2004; Chung et al., 1999; Hall et al., 2001; Mitchell et al., 2005). ROS production is a 
complex, dynamic phenomenon occurring during and after a period of cellular energy 
deprivation, e.g. acute I/R injury, predisposing the retina to oxidative damage (Abramov et 
al., 2007; Li et al., 2009). The ability to detect and quantify ROS in vivo and in real-time, is 
therefore essential to understanding their biological roles.    
Fluorescent detection or imaging with redox-responsive probes is a potentially powerful 
approach because of its merits of high sensitivity, easy visualization, simple operation, high 
spatial resolution in microscopic imaging techniques and most importantly in vivo application 
(Fernandez-Suarez and Ting, 2008; Wen-Xue and Xu, 2012; Xu et al., 2013). Previously, 
fluorescent techniques largely involved the irreversible reaction of a non-fluorescent probe 
molecule with a radical of interest to produce a detectable fluorescent product (Halliwell and 
Whiteman, 2004; Morrow et al., 2010; Wardman, 2007). Such ‘one-way’ detection 
methodologies can have limitations, as they are not able to respond to dynamic changes to the 
cellular redox environment. With the chemistry of the probe response being irreversible, such 
techniques therefore cannot be used to identify the potential therapeutic benefit of antioxidant 
intervention following the induction of a pro-oxidant stress. This ultimately prompted the 
development of reversible ‘two-way’ probes, with stable nitroxide radicals having significant 
potential in this regard (Morrow et al., 2010).  
Nitroxides have previously been employed to probe various biophysical and biochemical 
processes involving oxidative stress (Ahn et al., 2012; Hirosawa et al., 2012; Mitchell et al., 
2001; Wang et al., 2013), due to their high scavenger ability, reactivity to ROS (Ahn et al., 
2012) and on the basis of their metabolism to reduced hydroxylamine (Morrow et al., 2010). 
Various cellular redox processes are capable of mediating the conversion between the 
reduced hydroxylamine and the oxidized nitroxide species and hence the ratio of these two 
states is indicative of the overall “reducing capacity”, or redox environment, of the cell 
(Belkin et al., 1987; Morrow et al., 2010; Swartz, 1987, 1990). Covalently linking a nitroxide 
moiety to a fluorescent structure possessing excitation and emission profiles of biological 
relevance (Morrow et al., 2010), e.g. rhodamine, efficiently quenches the excited state that 
leads to fluorescence (Ahn et al., 2012; Blough and Simpson, 1988; Green et al., 1990). The 
removal of the nitroxide free radical through a one-electron reduction to the non-radical 
hydroxylamine, removes this quenching effect resulting in the restoration of the typical 
fluorescence of the fluorophore (Blough and Simpson, 1988). As the response of the 
nitroxide is reversible and is reflected in changes in the fluorescence emission, this enables a 
unique investigative tool with the potential to provide real-time insight into diseases of 
oxidative stress in the eye (Morrow et al., 2010). These probes have been described as 
profluorescent nitroxides (PFN) as the fluorescence is switched on through metabolic or 
chemical processes akin to prodrugs.  
We have developed a novel, reversible, PFN probe (methyl ester tetraethylrhodamine 
nitroxide; ME-TRN), based on the rhodamine class of fluorescent dyes. We chose this 
structure due to its excellent fluorescent quantum yields, high solubility and stability in water 
and most importantly for its selective accumulation by mitochondria in living cells (Johnson 
et al., 1980; Morrow et al., 2010). Here we evaluate the suitability of an ME-TRN probe as an 
in vivo, real-time reporter of retinal oxidative status. The utility of PFN probes to quantify 
oxidative status in isolated cells by flow cytometry and fluorescence imaging has been 
previously demonstrated (Ahn et al., 2012; Morrow et al., 2010) and to translate these 
findings to the retina, in vivo, we used an established model of complete, acute retinal 
ischemia followed by reperfusion. The generation of ROS following the ischemic insult 
provides a known, in vivo, pro-oxidant condition, upon which we based our initial 
investigations. The known antioxidant and free radical scavenger, lutein, has previously 
shown to protect macula and photoreceptors from phototoxicity and oxidative injury (Alves-
Rodrigues and Shao, 2004; Chucair et al., 2007; Li et al., 2009) and more recently the inner 
retinal neurons from ischemic-reperfusion challenge, possibly by reducing oxidative stress 
(Dilsiz et al., 2006; Li et al., 2009). Based on these findings, lutein is considered an effective 
antioxidant. Accordingly, we used lutein to verify the fluorescent redox response of our 
probe. A validated technique for the measurement of retinal oxidative status in vivo could 
have a major impact on the ability to assess other putative neuroprotective antioxidants for 
the treatment of glaucoma and other neurodegenerative diseases.   
 
2. Materials and Methods 
2.1 Animals and Treatments 
Albino Sprague-Dawley rats (female, ~250 g) obtained from the Animal Resources Centre 
(Canning Vale, WA, Australia) at 8 weeks of age, were housed at Herston Medical Research 
Centre Animal Facility (Royal Brisbane & Women’s Hospital, Australia). Animals were 
maintained in temperature and humidity controlled rooms (~37 ˚C and 60 – 70 % 
respectively), with food and water available ad libitum. A 12:12 hr light/dark cycle (lights on 
at 7 a.m.) was used, with illumination provided by overhead fluorescent white lights. 
 
 Animals were divided into four treatment groups for I/R studies: (i) control/non-ischemic 
(n= 9), (ii) acute I/R injury (n= 6), (iii) lutein (n= 7) or (iv) acute I/R injury + lutein (n= 6). 
Each group received an intravitreal injection of ME-TRN probe, prior to I/R or non-ischemic 
treatment. Lutein or vehicle 10 % dimethyl sulfoxide (DMSO) was administered by 
intraperitoneal injection 1 hour prior to I/R (see preparation below). 
 
Animals prepared for ERG and immunohistochemistry (n= 3) were administered ME-TRN 
probe to one eye with the contralateral eye serving as a control for comparison purposes. 
Control eyes received a 2 µl vehicle injection of 10 % DMSO in injectable saline.  
 
Experiments were conducted in accordance with the ‘Animal Care and Protection Act (QLD) 
2001’, ‘The Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes’ and the ARVO statement for the Use of Animals in Ophthalmic and Vision 
Research.  
2.2 ME-TRN administration 
Animals were anaesthetized by intraperitoneal injection (i.p.) of 75 mg/kg ketamine and 15 
mg/kg xylazine. Pupils were dilated with 1 % tropicamide and 2.5 % phenylepherine (Bausch 
and Lomb, Tampa, FL), and corneas anaesthetized with 0.5 % tetracaine hydrochloride 
(Chauvin Pharmaceuticals, Kingston-Upon-Thames, UK). ME-TRN (2 µl of 5 x 10-5 M in 10 
% DMSO / injectable water) was injected into the vitreous of both eyes using a 10 µL 
Hamilton syringe coupled to a 26 gauge needle, to give a final concentration of 2 µM. 
Intravitreal injections were made posterior to the superior limbus at a 45˚ angle, preventing 
the probe from being injected into the lens.  
The probe was permitted to disperse throughout the vitreous and accumulate in the retina for 
30 mins prior to recording pre-ischemic retinal images using a Micron III rodent fundus 
imaging system (Phoenix Research Labs, Pleasanton, CA, USA) equipped with rhodamine 
filters (Ex 556 / Em 590 nm). Pre-ischemic fundus images provided base line intensity 
measures for comparison of ME-TRN fluorescent signal change induced by superoxide 
production during reperfusion and for the potential ameliorative effect of antioxidant 
intervention. Data are expressed as fluorescence intensity as a percentage of pre-insult values. 
Fluorescent intensity was subsequently measured 5, 10, 15, 30, 45 and 60 mins post ischemic 
insult during the reperfusion phase. 
To ensure similar fundus images were captured pre- and post I/R injury, optic nerve and 
major retinal blood vessel locations were clearly indicated and pre-ischaemic camera and 
animal stage positioning were fixed; animals were simply lifted away from the Micron III to 
allow correct repositioning following treatment. Bright field images (consistent illumination 
settings) were captured at each time point to verify fundus location prior to capturing 
fluorescent images. For each experimental animal, consistent excitation illumination levels 
and gain settings were used to acquire the fluorescent intensity images and were maintained 
for each image captured throughout the treatment period.  
2.3 Image Analysis 
Colour fluorescent fundus images were imported into Image J (National Institutes of Health, 
Bethesda, MD, USA) and converted to 8-bit greyscale. Average pixel intensity across the 
isolated circular whole fundus image was calculated to provide fluorescence intensity values 
for each time point. To account for possible variability of absolute fundus fluorescence levels 
between animals due to probe diffusion or other confounding factors, data are presented as 
the change in fluorescent intensity at each time point during reperfusion as a percentage of 
the corresponding pre-ischemia value (mean ± SEM). 
2.4 Antioxidant Preparation 
Lutein (0.05 mg/ml) was prepared in injectable saline containing 10 % DMSO and 
administered (0.2 mg/kg i.p.) 1 hour prior to I/R insult (Li et al., 2009). 
2.5 Evaluating ME-TRN Toxicity on Retinal Tissue using Electroretinography (ERG) 
Full-field ERGs were recorded as previously described (Moxon-Lester et al., 2009) 1 day (n= 
3) and 8 days (n= 3) following ME-TRN administration to examine potential toxicity of the 
probe to the retina. ME-TRN probe was injected into the vitreous (as above) of the left eye, 
with the contralateral eye serving as the control. Briefly, rats were dark-adapted overnight 
and prepared for recording under dim red light using LED illumination (λmax  =  650 nm). 
After anaesthesia and mydriasis, reference electrodes were placed on each ear and a 
grounding electrode positioned subcutaneously on the back. A platinum wire recording 
electrode was positioned on each cornea, which was kept moist with GenTeal gel (Novartis 
Pharmaceuticals, NSW, Australia). Body temperature was maintained at 37 ˚C with an 
electric animal heating blanket. Rats were then placed in a custom-designed ganzfeld and 
subjected to the ERG flash stimuli. ERGs were recorded simultaneously from both eyes.  
Scotopic responses recorded at 1.2 log cd.s.m-2 were elicited with a photographic flash unit 
(Metz mecablitz 60CT4, Zirndorf, Germany). An average of 2-3 flashes were recorded with 
an interstimulus interval of 300 sec to allow complete recovery of b-wave amplitudes. 
Responses were amplified and recorded with a bioamplifier/analogue-to-digital converter 
(Powerlab/4ST, ADInstruments, Castle Hill, Australia), band-pass-filtered between 0.3 and 
1000 Hz, and digitized at 4 kHz.  
 2.6 Acute Retinal Ischemia by Elevation of IOP 
Unilateral retinal ischemia was induced as previously described (Holcombe et al., 2008; 
Moxon-Lester et al., 2009). Briefly, anaesthetized animals were immobilized by resting the 
front teeth over a horizontal stabilizing bar and securing the skull with adjustable rods 
inserted in the bony external ear canals. The anterior chamber was cannulated with a 30-
gauge needle attached to a reservoir containing 0.9 % NaCl. A micromanipulator was used to 
insert the needle into the anterior chamber parallel to the iris plane at the 12 o’clock position. 
Intraocular pressure was increased to 120 mmHg by elevation of the reservoir to 163 cm. 
Ocular ischemia was confirmed by the blanching of the iris and interruption of the retinal 
circulation. Leakage from the initial ME-TRN injection site was rarely seen, however if it 
transpired, animals were immediately removed from the study as complete ischaemia could 
not be verified. After 60 mins of elevated IOP, removal of the cannula allowed reperfusion, 
generating superoxide radicals upon restoration of blood flow. During reperfusion, retinal 
fluorescence generated by the ME-TRN probe was imaged at 5, 10, 15, 30, 45 and 60 mins. 
Corneal hydration was maintained throughout. 
2.7 Evaluating Retinal Damage using Immunohistochemistry 
Rats were euthanized with Lethabarb (200 mg/kg i.p., Virbac, NSW, Australia) 8 days 
following ME-TRN administration and I/R. Eyes were enucleated and fixed in 10 % neutral 
buffered formalin for 2 hours at room temperature. Posterior eye cups were cryoprotected 
with 30 % sucrose before mounting and freezing in OCT (Tissue Tek, ProSciTech, QLD, 
Australia). Transverse sections (10 µm) were cut using a cryostat and maintained at -20 ˚C 
until required for immunostaining, using standard methods. Slides were incubated overnight 
at room temperature with polyclonal rabbit anti-Glial Fibrillary Acidic Protein (GFAP; 
1:1000, DakoCytomation, Glostrup, Denmark), or polyclonal rabbit anti-Ionized Calcium 
Binding Adaptor molecule 1 (IBA-1; 1:2000, Wako, Osaka, Japan). Immunolabelling was 
visualized with Fluorolink Cy2 labelled goat-anti-rabbit IgG (Amersham BioSciences, 
Buckinghamshire, UK,) incubated for 90 mins at room temperature. Images were viewed 
with an Olympus, BX41TF microscope (Tokyo, Japan) equipped with epifluorescence and 
captured with an Olympus DP70 camera. Images were imported into Adobe Photoshop CS5 
for minor editing of contrast and sharpness. 
2.8 Data Analysis 
ERG and fluorescent intensity responses are expressed as the mean ± SEM. Statistical 
comparisons were made using a non-parametric Wilcoxon matched-pairs signed rank test for 
ERGs. 
Following confirmation with a D'Agostino-Pearson omnibus test that the fluorescence 
intensity data from each treatment group were normally distributed, the data were analyzed 
and compared with a linear model using R software (The R Foundation for Statistical 
Computing). P ≤ 0.05 was considered statistically significant. 
 
3. Results 
3.1 ME-TRN uptake in rat retina 
For the ME-TRN probe to be considered a suitable tool for the real-time measurement of 
retinal oxidative status in vivo, uptake into retina cells is necessary. Figure 1 shows a 
transverse section of rat retina confirming that the ME-TRN probe is selectively accumulated 
by retinal neurons following intravitreal administration. These data confirm that the observed 
changes in fundus fluorescence represent the response of retinal cells to changes in their 
cellular environment.  
3.2 ME-TRN administration and retinal function  
The ERG, commonly used to assess the functional integrity of the retina, allows for early 
detection and monitoring of adverse drug effects on the visual pathways. The a-wave is the 
response generated by photoreceptors (Penn and Hagins, 1969) and the b-wave is 
predominantly generated by the depolarization of the ON bipolar cells (Bush and Sieving, 
1996; Hood and Birch, 1996; Robson and Frishman, 1995; Robson and Frishman, 1998; 
Sieving et al., 1994). The oscillatory potentials (OPs) arise from activity in the inner retina, 
including a major contribution from amacrine cells (Wachtmeister and Dowling, 1978)	   Prior 
to employing and evaluating our ME-TRN probe as a real-time reporter of retinal oxidative 
status in vivo, we initially examined its ‘short and long term’ toxicity to retinal tissues and 
their function. 	  
ERG responses were recorded from ME-TRN and vehicle treated eyes at 1 day (short term) 
and 8 days (long term) post administration (Fig. 2). Vehicle and ME-TRN treated eyes 
showed no significant difference in a-wave amplitude (1 day: 345 ± 45 µV and 400 ± 77 µV 
respectively; p= 0.75, and 8 days: 408 ± 36 µV and 475 ± 84 µV respectively; p= 0.50) or b-
wave amplitude (1 day: 948 ± 131 µV and 1033 ± 150 µV respectively; p= 0.75, and 8 days: 
975 ± 82 µV and 1073 ± 128 µV respectively; p= 0.75) (Fig. 2b). Similarly, neither a-wave 
nor b-wave implicit times were affected by ME-TRN injection (a-wave – 1 day: 7.25 ± 0.29 
ms and 7.17 ± 0.22 ms, p≥ 0.99; 8 days: 7.67 ± 0.30 ms and 7.58 ± 0.08 ms, p≥ 0.99; b-wave 
– 1 day: 57.08 ± 7.83 ms and 55.67 ± 7.41 ms, p= 0.50; 8 days: 46.00 ± 0.76 ms and 50.42 ± 
3.36 ms, p= 0.25, for control and ME-TRN treated eyes respectively). No significant change 
in OP peak amplitude was observed (1 day: 69 ± 11 µV and 72 ± 12 µV, p≥ 0.99; 8 days: 61 
± 10 µV and 63 ± 10 µV, p= 0.99, for control and ME-TRN treated eyes respectively). These 
data suggest that the ME-TRN probe has no detrimental effect on retinal function and can be 
used at concentrations described.  
3.3 Immunohistochemistry  
To investigate possible toxic effects of the ME-TRN probe on the retina, we analyzed glial 
cell activation as the hallmark of reactive gliosis and neuroinflammation with GFAP 
(macroglia) and IBA-1 (microglia/macrophages) staining (Fig. 3).  
In the healthy retina, GFAP is the main intermediate filament protein in astrocytes, and has 
limited or no expression in Müller cells. Eight days after the intravitreal injection of ME-
TRN, GFAP immunoreactivity was still restricted to the astrocytes present in the nerve fibre 
layer. As reported previously (Larsen and Osborne, 1996), an acute I/R injury induced a 
drastic upregulation in GFAP immunoreactivity, significantly enhancing GFAP distribution 
to glial processes from the inner limiting membrane to the outer retina associated with 
activated Müller cells.   
In response to various stimuli, microglia transform into activated forms that can be 
distinguished by their morphology and antigenicity (Streit et al., 1988). When activated, the 
morphology of microglia include a rounded nucleus, abundant cytoplasm and short processes 
(Ito et al., 1998). IBA-1 labelled microglia (Fig. 3) in post I/R retina exhibit a morphology 
indicative of activation. However, no evidence of microglial activation could be seen in ME-
TRN treated retinas, which were qualitatively similar to control retinas. 
3.4 Quantification of Fluorescence Intensity following I/R Injury 
The reperfusion phase following an acute ischemic insult generates ROS that become highly 
damaging to cellular components when ROS overwhelms the cell’s intrinsic antioxidant 
capacity. The complete acute I/R rat model therefore provided a known, in vivo, pro-oxidant 
condition, upon which we based our investigations. 
The initial assessment of ME-TRN fluorescent intensity in non-ischemic control eyes, 
demonstrated that the probe’s fluorescence in the retina was relatively stable over a 120 min 
treatment period (60 mins of sham ischemia plus 60 mins imaging during sham reperfusion) 
(Fig. 4). Figure 5 shows that the production of superoxide upon restoration of blood flow 
following the ischemic insult resulted in a significant (F(5,30) = 2.864, p = 0.031) decrease in 
fundus fluorescence intensity over the 60 mins of reperfusion (white triangles) when 
compared to the non-ischemic, control group (white circles), with significant reductions seen 
at 10, 15, 30, 45 and 60 mins reperfusion; (72.17 ± 6.47 % vs 84.50 ± 4.18 % at 5 mins 
reperfusion vs pre-ischemia; p= 0.0577, 63.33 ± 4.09 % vs 79.50 ± 2.91 % at 10 mins; p= 
0.0075, 60.33 ± 4.42 % vs 76.88 ± 4.84 % at 15 mins; p= 0.0102, 60.67 ± 4.79 % vs 74.75 ± 
3.86 % at 30 mins; p= 0.0099, 52.20 ± 6.11 % vs 72.50 ± 4.35 % at 45 mins; p= 0.004, and 
47.17 ± 5.59 % vs 68.71 ± 5.42 % at 60 mins; p= 0.0013, respectively). The absence of 
reducing equivalents and the presence of oxygen resulted in the equilibrium between the 
oxidized nitroxide molecule and the reduced hydroxylamine being pushed towards the more 
oxidized form of the species (Morrow et al., 2010). This oxidized form is highly unstable and 
rapidly converts back to the non-fluorescent nitroxide radical state, resulting in the decrease 
in fluorescence we observed within this treatment group. 
In non-ischemic eyes, the intraperitoneal administration of the antioxidant lutein had no 
significant effect on ME-TRN retinal fluorescence throughout the treatment period (Fig. 5, 
black circles) when compared with the non-ischemic control group (F(5,36) = 1.354, p = 
0.245). This confirmed that any effects seen within the I/R + lutein treatment group were the 
result of the antioxidative properties of lutein reducing overall oxidative stress levels. 
Antioxidant intervention (black triangles) successfully ameliorated the decrease in retinal 
fluorescence induced by I/R injury (F(5,30) = 5.706, p= 0.001), with significantly increased 
fluorescence observed at 5, 10 and 15 mins into the reperfusion phase; (72.17 ± 6.47 % vs 
90.50 ± 5.86 % at 5 mins; p= 0.026, 63.33 ± 4.09 % vs 86.33 ± 7.61 % at 10 mins; p= 0.0047, 
60.33 ± 4.42 % vs  83.71 ± 2.25% at 15 mins; p= 0.0044,  60.67 ± 4.79 % vs 71.00 ± 3.97 % 
at 30 mins; p= 0.1573, 52.20 ± 6.11 % vs 64.00 ± 5.56 % at 45 mins; p= 0.1691, and 47.17 ± 




Pro-oxidants are recognized as having a crucial role in various biological processes including 
the regulation of normal physiological processes (Morrow et al., 2010; Nathan, 2003), 
however in excess, can lead to an imbalance in the redox environment and lead to a variety of 
disorders including cancer, I/R injury, and neurodegeneration (Dirani et al., 2011; Hess and 
Manson, 1984; Lin and Beal, 2006; Liu et al., 2007; Morrow et al., 2010; Tezel, 2006; Yapici 
et al., 2011). Techniques capable of quantifying and visualising the changes to the cellular 
redox environment of biological systems as a result of pro-oxidant or antioxidant processes 
are therefore crucial for understanding the mechanistic links between free radical chemistry 
and disease outcomes (Morrow et al., 2010). The most effective way to define this link is 
with the real-time measurement of redox changes occurring in live cells. We have designed 
and synthesized a novel reversible profluorescent probe, ME-TRN, based on a rhodamine 
fluorophore containing a nitroxide functional group. Here we demonstrate the successful 
application and in vivo evaluation of ME-TRN for the detection and quantification of retinal 
oxidative status in real-time. 
The retina is an ideal model for examining ROS-mediated pathological events, due to the 
high content of polysaturated fatty acid and high oxygen consumption (Bazan, 1988; Li et al., 
2009; Li and Lo, 2010). The rat retinal I/R model, which mimics clinical situations such as 
retinal vascular occlusion disease and acute glaucoma, is an established animal model for 
studying retinal cell responses after an ischemic insult (Cho et al., 2011; Sun et al., 2010). It 
is believed that impairment of mitochondrial integrity is a key factor in ROS-mediated 
neurodegeneration (Chrysostomou et al., 2013; Osborne and del Olmo-Aguado, 2013). 
Cellular events such as disruption of ion homeostasis, depletion of adenosine triphosphate 
stores and glutamate-induced excitotoxicity (Osborne et al., 2004; Pellegrini-Giampietro et 
al., 1990), occur during the challenge of oxidative stress (Aydemir et al., 2004; Block and 
Schwarz, 1997; Celebi et al., 2001; Li and Lo, 2010) resulting in increased levels of lipid 
peroxidation, depletion of free radical scavengers (Block and Schwarz, 1997; Chidlow et al., 
2002) and subsequent neurodegeneration. Conversely, the reduction of free radical formation 
and reduced oxidative stress can retard or prevent neuronal cell death in ischemic retina 
(Chidlow et al., 2002; Dilsiz et al., 2006; Li et al., 2009; Maher and Hanneken, 2008). ROS 
detection methods and antioxidants that target the mitochondria are therefore of high interest 
and importance.   
We have previously shown through confocal microscopy, that ME-TRN is taken up by living 
cells (RGC-5 cell line and fibroblasts), and is selectively accumulated in the mitochondria 
(Barnett et al., 2013). Similar nitroxide hybrids have been shown to localize to 
the mitochondria (Smith et al., 2008). The unique potential of our nitroxide-based probe to 
interconvert reversibly between the stable nitroxyl radical, the reduced hydroxylamine and 
oxidized oxoammonium forms has allowed for the first time, detection of ROS and the 
possible benefits of antioxidant therapy to be monitored in vivo, in real time.  
The ME-TRN probe response is driven by the overall reducing processes of the cellular 
environment and, in particular, by the mitochondria. The presence of the stable radical during 
oxidation short-circuits the normal fluorescence effect and so these systems possess low 
inherent fluorescent emission. Upon metabolism, redox processes or free radical scavenging 
reactions, the free radical is converted to the non-radical species that displays the bright 
fluorescence of the inherent chromophore (Blough and Simpson, 1988; Morrow et al., 2010). 
Previously, this redox-response of the probe was observed in vitro by stimulating superoxide 
production in fibroblast and RGC-5 cell cultures, through the inhibition of the mitochondrial 
respiratory chain with antimycin (Barnett et al., 2013). Here, for the first time, we show a 
similar response in vivo (rat retina I/R injury), demonstrating a significant decrease in probe 
fluorescence in response to a pro-oxidant stress. This fluorescence decrease was time 
dependent (F(5,30) = 2.864, p = 0.031, see Fig. 5), signifying the increased production and 
accumulation of ROS within the cellular environment during the reperfusion phase. The 
reduction of free radicals and oxidative stress through the administration of lutein (Dilsiz et 
al., 2006; Li et al., 2009) successfully ameliorated the I/R-induced decrease in retinal 
fluorescence. Antioxidant therapy can therefore be considered somewhat effective at 
maintaining the probe in the fluorescent reduced hydroxylamine state, limiting oxidation back 
to the nitroxyl radical form.  
During the past decade, numerous studies have investigated neuroprotective strategies to 
reduce / prevent retinal cell death. Recently, intensive efforts have been made to explicate the 
neuroprotective effects of carotenoids in ocular diseases in vivo (Li et al., 2009; Muriach et 
al., 2006; Sasaki et al., 2009) and in vitro (Li and Lo, 2010; Nakajima et al., 2009). Various 
carotenoids are present in human plasma, but only the xanthophylls lutein and zeaxanthin are 
found in retina in considerable amounts (Junghans et al., 2001). Lutein, a potent antioxidant, 
has been applied in human clinical trials and shown to improve vision and retard the 
progression of AMD and cataract development (Chasan-Taber et al., 1999; Itagaki et al., 
2006; Li et al., 2009; Li and Lo, 2010; Richer et al., 2007; Richer et al., 2004), however the 
mechanism of protection is unclear and the role of lutein in ischemic injury is limited (Li et 
al., 2012). In vitro studies show lutein can penetrate into cells and scavenge intracellular 
H2O2 preventing cell damage (Li and Lo, 2010) suggesting a possible therapeutic benefit to 
antioxidant intervention for diseases linked to oxidative stress. Our present results confirm 
that a single administration of lutein provides a degree of protection against oxidative stress. 
Whether a prolonged diet rich in antioxidants prior to a future ischemic injury could mitigate 
the deleterious effects of ROS requires further investigation. 
This study highlights the ability of the novel ME-TRN probe to detect, visualize and quantify 
oxidative stress in vivo. ERG analysis of a- and b-waves and OPs, also demonstrated that 
intraocular injection of ME-TRN had no effect on the functional integrity of the retina (Fig. 
2). Moreover, normal retinal status was confirmed in ME-TRN treated retinas through 
immunohistochemical studies: GFAP expression remained confined to astrocytes and IBA-1 
labelled microglia demonstrated minimal activation. This was in stark contrast to the glial cell 
activation we and others see in injured retinas (Fig. 3) (Larsen and Osborne, 1996; Naskar et 
al., 2002; Wang et al., 2000).	  These data suggest that ME-TRN can be safely administered in 
the eye to monitor the dynamic processes of oxidative stress. In this study, we used ME-TRN 
to detect ROS production in an acute model of ischaemia, which predominantly induces inner 
retinal damage. Figure 1 demonstrates that ME-TRN is not only taken up by the inner retinal 
neurons, but is also avidly accumulated in the outer nuclear layer. The advantage of ME-TRN 
accumulation throughout the retina should also allow the detection of ROS production in 




In summary, this study documents a new technique for the real-time measurement of retinal 
oxidative status in vivo. This could potentially have a major impact on the ability to assess 
putative neuroprotective antioxidants for the treatment of retinal and other neurodegenerative 
diseases. The mechanisms underlying retinal degeneration in a number of ocular disease 
states like glaucoma, age-related macular degeneration and retinal ischemia are complex. 
However it is becoming increasingly evident that mitochondrial dysfunction, superoxide 
generation and oxidative stress play a significant role. The ability to quantify such changes in 
vivo is of great value. Reversible PFN probes provide a possible avenue for this 
quantification. The ME-TRN probe has proven effective at detecting alterations in the 
cellular redox status in vivo and hence provides a unique investigative tool allowing real-time 
insight into a variety of disorders linked to oxidative stress.	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FIGURE 1: Transverse frozen section of rat retina showing accumulation and fluorescence 
of ME-TRN probe in neurons (arrows) 60 mins after a single intravitreal injection (2 µM). 
Brightest fluorescence seen in the outer nuclear layer (ONL) with weaker fluorescence 




FIGURE 2: ERG analysis of vehicle control and ME-TRN injected eyes, 1 and 8 days post 
treatment (n= 3, mean ± SEM). (a) Representative traces of the scotopic ERG waveforms 
recorded with a stimulus of 1.2 log cd.s.m-2 showing no apparent change in a-wave, b-wave 
or oscillatory potential amplitude or peak latency. (b) Quantification of a- and b-wave 
amplitudes confirming no significant effect of ME-TRN (2 µM) injection upon retinal 
function.  
 
FIGURE 3: GFAP and IBA-1 immunohistochemistry of rat retinas 8 days after the 
intravitreal injection of ME-TRN (2 µM). No differences in labelling were apparent between 
control and ME-TRN trerated retinas. GFAP immunoreactivity was restricted to the 
astrocytes whilst IBA-1 positive microglia displayed the resting ramified morphology. In 
contrast, an ischemic insult followed by 8 days of reperfusion resulted in a significant 
upregulation in GFAP immunoreactivity associated with activated Müller cells. I/R also 
resulted in the activation of microglia (IBA-1), which displayed a rounded nucleus, abundant 
cytoplasm and shorter processes. Higher magnification insets show microglia nuclei in each 
condition of activation. 
	    
 	  
FIGURE 4: In vivo fundus imaging showing the time-course of ME-TRN fluorescence 
(556/590 nm) in the rat eye during reperfusion following an acute ischemic insult, and the 
effect of the antioxidant lutein (0.2 mg/kg). Fundus fluorescence was stable in non-ischemic 
retinas throughout the 60 min ‘reperfusion’ period (top rows). In contrast, reactive oxygen 
species generated during the reperfusion phase after acute ischemia resulted in a marked, 
time-dependent, decrease in probe fluorescence (third row). Pre-ischemic antioxidant 
treatment ameliorated the I/R-induced decrease in retinal fluorescence (bottom row). 
	    
  
FIGURE 5: Quantification of ME-TRN fluorescence captured in the rat fundus in vivo 
during 60 mins of reperfusion following an acute ischemic insult. Data presented as the 
change in fluorescence intensity at each time point as a percentage of the pre-ischemic (time 
= 0) value for each eye (mean ± SEM). An ischemic insult resulted in a marked decrease in 
fluorescent intensity over the 60 mins of reperfusion (I/R) when compared to the non-
ischemic control group, with significant reductions seen at 10, 15, 30, 45 and 60 mins 
reperfusion (* p < 0.05 compared with non-ischemic control). An intraperitoneal injection of 
lutein (0.2 mg/kg) 1 hour prior to the ischemic insult ameliorated the decrease in fluorescence 
observed in I/R animals, with significant improvements observed after 5, 10 and 15 mins of 
reperfusion († p < 0.05 compared with I/R alone).   
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